Details

Autor(en) / Beteiligte

• Huh, Kyungmin
• Chung, Doo Ryeon
• Ha, Young Eun
• Ko, Jae-Hoon
• Huh, Hee Jae
• Lee, Nam Yong
• Cho, Sun Young
• Kang, Cheol-In
• Peck, Kyong Ran
• Song, Jae-Hoon

Titel

Impact of vancomycin resistance in Enterococcus faecium bloodstream infection on mortality: A retrospective analysis of nationwide surveillance data

Ist Teil von

• International journal of infectious diseases, 2023-09, Vol.134, p.8-14

Ort / Verlag

Canada: Elsevier Ltd

Erscheinungsjahr

2023

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• •The impact of vancomycin resistance in enterococcal bacteremia is controversial.•Monomicrobial Enterococcus faecium bacteremia was collected through multicenter surveillance.•Vancomycin resistance was independently associated with all-cause mortality.•Pitt score and inappropriate definitive antibiotics were associated with mortality.•Further efforts must be made to mitigate the spread of vancomycin-resistant enterococci and to improve therapy. It is unclear whether the poor outcome of patients with severe vancomycin-resistant enterococci (VRE) infection is attributable to vancomycin resistance or to Enterococcus faecium (Efm), which predominates among VRE. Retrospective study of a prospectively identified cohort from nationwide surveillance. A cohort of consecutive, nonduplicate episodes of monomicrobial bloodstream infections (BSIs) caused by Efm in 2016 was selected. The primary outcome was all-cause, 30-day, in-hospital mortality. Inverse probability weighting was applied using the propensity score for vancomycin-resistant Efm (VREfm) BSI. A total of 241 Efm BSI episodes were included, of which 59 (24.5%) were VREfm. Patients with VREfm BSI were younger but had similar comorbidities to those with vancomycin-sensitive Efm (VSEfm) BSI. Multivariable logistic regression revealed that younger age, previous piperacillin-tazobactam use, and steroid use were significant risk factors for VREfm BSI, but 30-day in-hospital mortality did not differ significantly between groups (35.6% and 23.6% for VREfm and VSEfm, respectively; odds ratio, 1.79; 95% confidence interval, 0.95-3.37; P = 0.101). However, Cox regression with inverse probability weighting revealed that vancomycin resistance was independently associated with an increased risk of mortality (adjusted hazard ratio, 2.18; 95% confidence interval, 1.03-4.62; P = 0.041). In patients with Efm BSI, vancomycin resistance was independently associated with mortality.